Age matters: older age as a risk factor for CMV reactivation in the CMV serostatus-positive kidney transplant recipient

被引:26
作者
Hemmersbach-Miller, Marion [1 ,2 ]
Alexander, Barbara D. [1 ]
Pieper, Carl F. [3 ]
Schmader, Kenneth E. [4 ,5 ]
机构
[1] Duke Univ, Med Ctr, Div Infect Dis, Durham, NC 27708 USA
[2] Duke Clin Res Inst, Durham, NC 27701 USA
[3] Duke Univ, Dept Biostat & Bioinformat, Durham, NC USA
[4] Duke Univ, Div Geriatr, Med Ctr, Durham, NC USA
[5] Durham VA, GRECC, Durham, NC USA
基金
美国国家卫生研究院;
关键词
Older adults; Cytomegalovirus; Kidney transplantation; Infection; PREVENT CYTOMEGALOVIRUS DISEASE; CELL-MEDIATED-IMMUNITY; VALGANCICLOVIR PROPHYLAXIS; PREEMPTIVE VALGANCICLOVIR; GANCICLOVIR THERAPY; ORAL GANCICLOVIR; GRAFT-SURVIVAL; INFECTION; IMPACT; MANAGEMENT;
D O I
10.1007/s10096-019-03744-3
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Evaluate risk factors for cytomegalovirus (CMV) reactivation during the first year after kidney transplantation in the CMV-seropositive older recipient. Retrospective single-center study. Between 2011 and 2015, 91 patients >= 65 years received a kidney transplant; these were matched with 91 controls, aged 40-60. Risk of CMV reactivation in the CMV-seropositive recipients was analyzed. Sixty-three older and 54 younger recipients were included; 50% had received CMV-directed prophylaxis. CMV reactivation was significantly more frequent in the older group (71.4% vs 44.4%, p = 0.003) and occurred earlier (p = 0.003). A multivariate model showed that only age was associated with CMV reactivation (OR 2.48, p = 0.03). After excluding patients that received thymoglobulin, older age group remained the only risk factor of CMV reactivation (OR 3.81, p = 0.014). Recurrent event analysis showed that the older cohort had an HR of 1.94 (p = 0.01) of CMV viremia; there was significant episode-cohort interaction (p < 0.01). While the older group had a higher risk of infection (HR = 2.43), after the initial episode the relative hazards were approximately equal (HR = 1.08, at period 2). This suggests that it is key to specifically avoid the first episode of reactivation. Universal prophylaxis or a hybrid prophylaxis model should be considered in the CMV-seropositive kidney transplant recipient aged >= 65 years.
引用
收藏
页码:455 / 463
页数:9
相关论文
共 43 条
[21]   Impact of cytomegalovirus in organ transplant recipients in the era of antiviral prophylaxis [J].
Limaye, Ajit P. ;
Bakthavatsalam, Ramasamy ;
Kim, Hyung W. ;
Randolph, Sara E. ;
Halldorson, Jeffrey B. ;
Healey, Patrick J. ;
Kuhr, Christian S. ;
Levy, Adam E. ;
Perkins, James D. ;
Reyes, Jorge D. ;
Boeckh, Michael .
TRANSPLANTATION, 2006, 81 (12) :1645-1652
[22]   Clinical Utility of Cytomegalovirus Cell-Mediated Immunity in Transplant Recipients With Cytomegalovirus Viremia [J].
Lisboa, Luiz F. ;
Kumar, Deepali ;
Wilson, Leticia E. ;
Humar, Atul .
TRANSPLANTATION, 2012, 93 (02) :195-200
[23]   Definitions of Cytomegalovirus Infection and Disease in Transplant Patients for Use in Clinical Trials [J].
Ljungman, Per ;
Boeckh, Michael ;
Hirsch, Hans H. ;
Josephson, Filip ;
Lundgren, Jens ;
Nichols, Garrett ;
Pikis, Andreas ;
Razonable, Raymund R. ;
Miller, Veronica ;
Griffiths, Paul D. .
CLINICAL INFECTIOUS DISEASES, 2017, 64 (01) :87-91
[24]   Effect of Cytomegalovirus Infection on Survival of Older Kidney Transplant Patients (D plus /R plus ): Impact of Valganciclovir Prophylaxis Versus Preemptive Therapy [J].
Luna, E. ;
Caravaca, F. ;
Ferreira, F. ;
Fernandez, N. ;
Martin, P. ;
Vargas, M. L. ;
Vargas, M. L. ;
Saenz de Santamaria, J. ;
Garcia Pino, G. ;
Azevedo, L. ;
Munoz Sanz, A. .
TRANSPLANTATION PROCEEDINGS, 2016, 48 (09) :2931-2937
[25]   Can Preemptive Cytomegalovirus Monitoring Be As Effective As Universal Prophylaxis When Implemented As the Standard of Care in Patients at Moderate Risk? [J].
McGillicuddy, John W. ;
Weimert, Nicole A. ;
Taber, David J. ;
Turner, Annie ;
Mitchell, Larrissa A. ;
Wray, Dannah W. ;
Egidi, Maria F. ;
Kuppachi, Sarat ;
Hughes, Michael G. ;
Baliga, Prabhakar K. ;
Chavinl, Kenneth D. .
TRANSPLANTATION, 2010, 89 (10) :1218-1223
[26]   Exponentially increased risk of infectious death in older renal transplant recipients [J].
Meier-Kriesche, HU ;
Ojo, AO ;
Hanson, JA ;
Kaplan, B .
KIDNEY INTERNATIONAL, 2001, 59 (04) :1539-1543
[27]   Infectious complications among 620 consecutive heart transplant patients at Stanford University Medical Center [J].
Montoya, JG ;
Giraldo, LF ;
Efron, B ;
Stinson, EB ;
Gamberg, P ;
Hung, S ;
Giannetti, N ;
Miller, J ;
Remington, JS .
CLINICAL INFECTIOUS DISEASES, 2001, 33 (05) :629-640
[28]  
Mouton CP, 2001, AM FAM PHYSICIAN, V63, P257
[29]   Cytomegalovirus prophylaxis and graft outcome in solid organ transplantation:: A collaborative transplant study report [J].
Opelz, G ;
Döhler, B ;
Ruhenstroth, A .
AMERICAN JOURNAL OF TRANSPLANTATION, 2004, 4 (06) :928-936
[30]   Cytomegalovirus in Solid Organ Transplantation [J].
Razonable, R. R. ;
Humar, A. .
AMERICAN JOURNAL OF TRANSPLANTATION, 2013, 13 :93-106